MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-18-2026
Processa Pharmaceuticals ROE Ratio 2011-2026 | PCSA
Annual ROE Ratio Processa Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -243.2 | -698.64 | -222.91 | -367.09 | -44.84 | -62.83 | -41.91 | -38.81 | -497.45 | 14.29 | 169.51 | -374.71 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 169.51 | -698.64 | -200.72 |
Quarterly ROE Ratio Processa Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -294.66 | -326.72 | -312.28 | -171.63 | -200.68 | -138.76 | -117.3 | -97.22 | -132.15 | -138.02 | -135.22 | -74.53 | -85.5 | -61.56 | -46.64 | -28.48 | -41.86 | -44.27 | -36.67 | -20.4 | -31.17 | -28.56 | -37.46 | -32.24 | -41.03 | -39.05 | -39.39 | -32.53 | -202.39 | -384.29 | -446.47 | -497.45 | -317.26 | -91.38 | 7.67 | 81.91 | 86.52 | 66.27 | 145.49 | 151.17 | 85.61 | 5.1 | -169.02 | -247.32 | -290.34 | -267.8 | -240.82 | -135.36 | -158.85 | -139.32 | -114.38 | -42.03 | -42.03 | -18.54 | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 151.17 | -497.45 | -110.39 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
-36.22 | $ 3.73 | - | $ 8.97 B |  Australia |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
39.76 | $ 333.39 | - | $ 43.7 B | USA |
 |
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
-55.11 | - | 4.14 % | $ 49.1 M | USA |
 |
Burford Capital Limited
BUR
|
10.1 | $ 4.73 | - | $ 784 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Cabaletta Bio
CABA
|
-149.8 | $ 3.4 | - | $ 342 M | USA |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M | France |
 |
Aligos Therapeutics
ALGS
|
-45.18 | $ 7.42 | - | $ 73.3 M | USA |
 |
Allakos
ALLK
|
-110.0 | - | - | $ 28.6 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-175.75 | $ 3.17 | - | $ 5.22 M |  Israel |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M | Israel |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Therapeutics
APLT
|
698.49 | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-716.17 | - | -13.39 % | $ 1.45 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
103.22 | - | -2.5 % | $ 5.88 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-350.48 | $ 2.75 | 4.16 % | $ 1.22 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
12.44 | $ 21.68 | - | $ 1.01 B | USA |
 |
CymaBay Therapeutics
CBAY
|
-36.05 | - | - | $ 3.45 B | USA |
 |
BioNTech SE
BNTX
|
1.11 | $ 99.47 | - | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K | USA |
 |
ContraFect Corporation
CFRX
|
549.72 | - | -5.16 % | $ 5.39 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
-16.39 | $ 1.55 | - | $ 399 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
248.9 | $ 4.24 | - | $ 453 M | USA |
 |
Galectin Therapeutics
GALT
|
24.11 | $ 2.56 | - | $ 164 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-8.52 | $ 24.58 | - | $ 3.13 B | USA |
 |
AIkido Pharma
AIKI
|
-32.34 | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
45.18 | - | -4.8 % | $ 255 M | USA |
 |
Genmab A/S
GMAB
|
24.88 | $ 29.3 | - | $ 18.8 B |  Danmark |
 |
Autolus Therapeutics plc
AUTL
|
-161.42 | $ 1.49 | - | $ 397 M | Britain |
 |
Aptose Biosciences
APTO
|
93.75 | - | -45.71 % | $ 1.2 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
6.58 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Checkpoint Therapeutics
CKPT
|
445.47 | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
-67.58 | - | -16.75 % | $ 25.8 M | USA |
 |
Celldex Therapeutics
CLDX
|
-49.08 | $ 33.87 | - | $ 2.25 B | USA |
 |
AVROBIO
AVRO
|
12.83 | - | 1083.1 % | $ 745 M | USA |
 |
Clearside Biomedical
CLSD
|
204.15 | - | - | $ 25.3 M | USA |